Sarepta Therapeutics (SRPT) Accounts Payables (2010 - 2026)

Sarepta Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $70.4 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 54.92% year-over-year to $70.4 million in Q1 2026; TTM through Mar 2026 was $70.4 million, a 54.92% decrease from a year earlier, with the FY2025 full-year figure at $280.8 million, up 30.96% from the prior year.
• Accounts Payables slipped to $70.4 million in Q1 2026 per SRPT's latest filing, from $280.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $280.8 million in Q4 2025 and bottomed at $54.0 million in Q1 2022.
• The 5-year median for Accounts Payables is $107.4 million (2024), against an average of $121.4 million.
• Across the five-year window, Accounts Payables jumped 168.24% in 2022 and sank 54.92% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $95.9 million in 2022, then soared by 72.01% to $164.9 million in 2023, then jumped by 30.03% to $214.4 million in 2024, then soared by 30.96% to $280.8 million in 2025, then tumbled by 74.94% to $70.4 million in 2026.
• Per Business Quant, the three latest SRPT Accounts Payables figures stand at $70.4 million (Q1 2026), $280.8 million (Q4 2025), and $94.0 million (Q3 2025).